Peer-reviewed veterinary case report
Comparing Vincristine Alone vs Vincristine with L-Asparaginase
By Setthawongsin, Chanokchon et al.·Published in Frontiers in veterinary science·2019·Department of Veterinary Pathology·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Conventional-Vincristine Sulfate vs. Modified Protocol of Vincristine Sulfate and L-Asparaginase in Canine Transmissible Venereal Tumor.
- Species:
- dog
Plain-English summary
A group of dogs with canine transmissible venereal tumor (CTVT) were treated with either a standard chemotherapy drug called vincristine or a combination of vincristine and L-asparaginase. Both treatment methods reduced the size of the tumors, but the combination therapy worked faster and showed promising results in terms of tumor response. This suggests that using both drugs together could be a more effective option for treating CTVT in dogs.
People also search for: dog cancer treatment vincristine · canine transmissible venereal tumor therapy · L-asparaginase for dogs
Abstract
Vincristine (VCR) is a mono-chemotherapy for canine transmissible venereal tumor (CTVT). L-asparaginase (LAP) is usually used in combination with other drugs. Previously, LAP-VCR protocol was applied for the CTVT-VCR-resistant cases. However, there were a few reports about using this protocol since the first visit.To firstly investigate the effectiveness of combining chemotherapy (Vincristine and L-asparaginase, VCR-LAP) in normal CTVT case. Secondly, to compare this protocol with the conventional (Vincristine, VCR) protocol before and during treatment in 24 CTVT dogs.Clinical signs, tumor relative volume, and histopathological change [amount of CTVT cells, tumor-infiltrating lymphocytes (TILs), TILs/CTVT ratio, collagen area, and Ki-67 proliferative index (PI)] were the treatment evaluation parameters. Moreover, transcriptome analysis of apoptotic (), drug-resistant genes (), and BCL-2 and BAX expression were also included.Both protocols gave the decreased tumor volume, increased TILs/CTVT ratios and collagen area in the mass. Interestingly, the combination protocol decreased treatment time. There were two resistant cases after treatment with VCR. The expression ofandwere decreased, and this may indicate the better response after treatment. Moreover, both drug resistant genes did not increase after treatment.The main finding of this study is that the combination protocol did not only decrease treatment duration time but also gave the effectiveness of treatment outcomes in CTVT cases. Therefore, the application of the new protocol could be used by the field practitioners.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31620453/